Physician profile
Bonnie Her
NPI 1932457736
$4,562.38
in general payments reported to CMS, 2019-2025
33 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $275 · 2021: $60.18 · 2022: $307 · 2023: $876 · 2024: $1,085 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.30 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $897.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $668.78 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $356.28 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.81 | 2022-2025 | Jardiance |
| Abbvie INC. | $253.42 | 2021-2025 | |
| Lilly USA, LLC | $245.43 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $236.81 | 2022-2025 | Veozah |
| Glaxosmithkline, LLC. | $234.38 | 2020-2025 | Trelegy Ellipta, Rotarix, Pediarix |
| Otsuka America Pharmaceutical, INC. | $208.47 | 2023-2025 | Rexulti |
| Pfizer INC. | $207.09 | 2022-2025 | |
| Amgen INC. | $127.73 | 2023-2025 | Repatha, Repatha, Otezla |
| Ironwood Pharmaceuticals, INC | $98.54 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $81.43 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $72.30 | 2023-2025 | Seglentis, Zoryve, Livalo |
| Abbott Laboratories | $63.61 | 2024-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $59.77 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $55.40 | 2022-2023 | Nexplanon |
| Dynavax Technologies Corporation | $47.24 | 2023 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $44.90 | 2023-2025 | |
| Arbor Pharmaceuticals, INC. | $41.44 | 2020 | |
| Lundbeck LLC | $40.98 | 2024 | Rexulti |
| Sobi, INC | $29.17 | 2022 | |
| Hologic Sales and Service, LLC | $23.80 | 2025 | Thinprep 2000 Processor |
| Boston Scientific Corporation | $22.01 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.34 | 2022 | |
| Kaleo, INC. | $19.93 | 2022 | |
| Inspire Medical Systems, INC. | $19.89 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2021 | |
| Esperion Therapeutics, INC. | $16.30 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $15.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.68 | 2024 | Voquezna |
| Dexcom, INC. | $14.08 | 2024 | Dexcom G6 Transmitter |
| Circassia INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Her listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.